アンジオテンシン受容体拮抗薬は血圧と心拍に関する日内リズムを同調させる<要約> by Ryo Sato
  
Nagoya City University Academic Repository 
 
 
 
学 位 の 種 類 
 
 
  博士 (医学) 
 
報 告 番 号 
 
  甲第１４５７号 
 
学 位 記 番 号   第１０４３号 
 
氏    名 
 
 
  佐藤 諒 
 
 
授 与 年 月 日 
 
 
  平成 27 年 3 月 25 日 
 
 
 
 
 
学位論文の題名 
 
 
 
 
 
Angiotensin receptor blockers regulate the synchronization of 
circadian rhythms in heart rate and blood pressure 
(アンジオテンシン受容体拮抗薬は血圧と心拍に関する日内リズムを同調
させる) 
 
J Hypertension, 31(6):1233-1238,2013 
 
 
 
 
論文審査担当者 
 
 
  主査： 早野 順一郎 
  副査： 伊藤 猛雄, 大手 信之 
 
 
It has been suggested that the sympathetic nervous system may play an important role in blood 
pressure (BP) regulation even in the early stages of chronic kidney disease (CKD) [1,2]. In addition, 
variability of circulatory dynamics fluctuated less as sympathetic function is activated [3,4]. 
Furthermore, inhibitors of the renin-angiotensin system (RAS) are known to suppress sympathetic 
nerve activity [5–7]. Finally, we have reported that an angiotensin II receptor blocker (ARB) 
restored the circadian BP rhythm [8,9]. On the basis of these findings, we analyzed the synchronicity 
in circadian rhythms of both heart rate (HR) and BP, as well as HR variability (HRV, SD), in 
relation to renal function in CKD before and during treatment with ARB. Our hypothesis is that the 
ratio of [day/night ratio of HR] over [day/night ratio of MAP] was increased as renal function 
deteriorated at baseline, and became independent of renal function during ARB treatment. 
To understand the role of the sympathetic system, we examined the relationship between 
day/night ratios of both HR and mean arterial pressure (MAP) as well as HR variability (HRV, SD) 
before and during an 8-week treatment with ARB, olmesartan, in 45 patients with CKD. 
The day/night HR ratio strongly correlated with the day/night MAP ratio before and during 
ARB treatment. The ratio of [day/night HR ratio] over [day/night MAP ratio] was increased as renal 
function deteriorated at baseline (r = -0.31, P = 0.04), and it was attenuated (1.10±0.10 to 1.06±0.10; 
P = 0.04) and became independent of renal function during ARB treatment (r = -0.04, P = 0.8). ARB 
increased both the day/night HR ratio (1.17±0.09 – 1.21±0.13; P = 0.04) and HRV (10.6±2.9 – 
11.7±4.2; P = 0.04), which were lower when baseline renal function deteriorated. 
The present study indicates that there exists a close correlation in circadian rhythms 
between HR and MAP in CKD. Synchronization between the two rhythms was progressively lost as 
renal function deteriorated, and ARB partly restored the synchronization. These findings suggest that 
the sympathetic nervous system is activated as renal function deteriorates, and ARB may suppress its 
activation. 
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